Celgene Corp. (NASDAQ: CELG) has decided to join the stock split game. Stock splits do not create any fundamental change on the surface, but the problem that Celgene has faced is that the run up in shares has lowered its average …
Celgene (NASDAQ: CELG) stock has been in my investment portfolio since 2013. I enjoyed a couple of great years with the biotech stock performing really well. Over the past couple of years, however, Celgene hasn't generated high …
This article is the second in a two-part series on applying the principles of value investing. In part 1 found here my primary focus was on the benefits of investing in fundamentally strong dividend growth stocks when they are out of favor, and …
Celgene Corporation's (NASDAQ:CELG) stock were down more than 5% in premarket trade following news of a drug development disappointment. In after-hours on Thursday, the pharmaceutical firm announced it would not take a …
“We expect recent increased nervousness on Celgene stock to prevail given various sell-side and bearish commentary has picked up,” Jefferies analyst Michael Yee wrote in a note.
Celgene Corp.'s stock CELG, -1.16% climbed 1.5% in premarket trade Thursday, after the biotechnology company was upgraded by J.P. Morgan analyst Cory Kasimov, who cited an "increasingly attractive valuation" and an impressive …
If you're looking for a smart stock to buy right now, look no further than Celgene (NASDAQ: CELG). The big biotech has hit a rough patch lately, with a major clinical setback, missing third-quarter revenue expectations, and lowering its full …
Biotech blue-chip stock ... for Celgene and its shareholders. You may not be able to follow all of its partnered programs, but you should certainly be keeping a close eye on these three. 1. OncoMed Pharmaceuticals (NASDAQ: OMED) …
Investors applauded Celgene Corp.’s fourth stock split in the last 14 years on Thursday by boosting shares of the biotechnology company by nearly $5. Celgene /quotes/zigman/69584/delayed /quotes/nls/celg CELG will do a 2-for-1 …